Natco Pharma receives favourable judgement, FMC appeal dismissed

Natco Pharma Limited has announced that Double Bench of the High Court of Delhi has dismissed an appeal filed by FMC Corporation, FMC Singapore and FMC India and has upheld prima facie the Judgement of the Single Judge that the Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.

Lupin launches Rufinamide Tablets USP in the US

Global pharma major Lupin Limited (Lupin) announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg, to market a generic equivalent of Banzel® Tablets, 200 mg and 400 mg, of Eisai Inc. Rufinamide Tablets (RLD Banzel) had estimated annual sales of USD 138 million in the U.S. (IQVIA MAT October 2022).